A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

NCT03071094 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
14
Enrollment
INDUSTRY
Sponsor class

Stopped The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and nivolumab in their respective pivotal trials (i.e., PHOCUS and CheckMate 459).

Conditions

Interventions

Sponsor

Transgene